Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer

Imunon, Inc.

Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.
Base salary of $475,000, target bonus of 50%; received inducement option for 80,000 shares at $0.88/share and 20,000 restricted shares.
He will oversee clinical programs including IMNN-001 (IL-2) for ovarian cancer; topline data from OVATION 2 Study expected Q2 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Sébastien Hazard

Executive Vice President and Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2023-12-11
Filed: December 11, 2023, 6:59 PM ET

On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Sébastien Hazard was appointed as Executive Vice President and Chief Medical Officer at Imunon, Inc..

Action: appointed
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-044323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.